About: Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context.
Creator	Mirazimi, Ali Leclipteux, Thierry Mertens, Pascal Jassoy, Christian Lagrou, Katrien Vandenberg, Olivier Cuypers, Lize Monteil, Vanessa Ranst, Marc Mileto, Davide Bouzet, Justine Brancart, Françoise Bry, François Cantinieaux, Brigitte Corazza, Francis Cotton, Fréderic De Vos, Nathalie Delaunoy, Sabrina Dresselhuis, Maud Gulbis, Béatrice Magein, Henri Mahadeb, Bhavna Martiny, Delphine Melin, Pierrette Roels, Olivier Serrano, Gabriela Stoffels, Karolien Vanderlinden, Jacques Wautier, Magali Yin, Nicolas Van, Sigi Wijngaert, Den Hospital, Luigi Sacco, Milan
source	MedRxiv
abstract	Introduction: COVID-19 Ag Respi-Strip, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen, has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions. In this Original Research article, we describe the conception, the analytical and clinical performances as well as the risk management of implementing the COVID-19 Ag Respi-Strip in a diagnostic decision algorithm. Materials and Methods: Development of the COVID-19 Ag Respi-Strip resulted in a ready-to-use ICT assay based on a membrane technology with colloidal gold nanoparticles using monoclonal antibodies directed against the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen. Four hundred observations were recorded for the analytical performance study and thirty tests were analysed for the cross-reactivity study. The clinical performance study was performed in a retrospective multi-centric evaluation on aliquots of 328 nasopharyngeal samples. COVID-19 Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics. Results: In the analytical performance study, the reproducibility showed a between-observer disagreement of 1.7%, a robustness of 98%, an overall satisfying user friendliness and no cross-reactivity with other virus-infected nasopharyngeal samples. In the clinical performance study performed in three different clinical laboratories we found an overall sensitivity and specificity of 57.6% and 99.5% respectively with an accuracy of 82.6%. The cut-off of the assay was found at Ct<22. User-friendliness analysis and risk management assessment through Ishikawa diagram demonstrate that COVID-19 Ag Respi-Strip may be implemented in clinical laboratories according to biosafety recommendations. Conclusion: The COVID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 minutes. Its role in the proposed diagnostic algorithm is complementary to the currently-used molecular techniques.
has issue date	2020-04-29(xsd:dateTime)
bibo:doi	10.1101/2020.04.24.20077776
has license	medrxiv
sha1sum (hex)	bb1c1c4784b6b5aebb93b4769c0c102b11eb296d
schema:url	https://doi.org/10.1101/2020.04.24.20077776
resource representing a document's title	Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context.
resource representing a document's body	covid:bb1c1c4784b6b5aebb93b4769c0c102b11eb296d#body_text
is schema:about of	named entity 'rapid' named entity 'study' named entity 'clinical' named entity 'COVID-19' named entity 'qRT-PCR' named entity 'decision algorithm' named entity 'compared' named entity 'COVID-19' named entity 'observations' named entity 'patients' named entity 'SARS-CoV-2' named entity 'highly conserved' named entity 'nucleoprotein' named entity 'SARS-CoV' named entity 'monoclonal antibodies' named entity 'SARS-CoV-2' named entity 'quarantine' named entity 'assay' named entity 'COVID' named entity 'antigen' named entity 'coronaviruses' named entity 'peer review' named entity 'viruses' named entity 'patient care' named entity 'first-line' named entity 'tested positive' named entity 'antibodies' named entity 'COVID' named entity 'preprint' named entity 'peer review' named entity 'preprint' named entity 'nasopharyngeal' named entity 'quality controls' named entity 'gene' named entity 'original research' named entity 'triage' named entity 'preprint' named entity 'nucleoprotein' named entity 'COVID-19' named entity 'COVID' named entity 'Control line' named entity 'sputum' named entity 'COVID' named entity 'COVID' named entity 'NanoQ' named entity 'Sciensano' named entity 'viral load' named entity 'medical devices' named entity 'lab coat' named entity 'cut-off' named entity 'preprint' named entity 'algorithm'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software